Arthritis research

PARE0017 EXPLORING DIFFERENCES IN THE AGE ONSET OF JIA BETWEEN MALES AND FEMALES: A PARENT-LED SURVEY

Richard Beesley1, Simon Stoner2, 1 Juvenile Arthritis Research, Torbridge, United Kingdom; 2University of Leeds, School of Healthcare, Leeds, United Kingdom

Background: The etiology of Juvenile Idiopathic Arthritis (JIA) remains unknown, despite a range of proposed mechanisms under investigation [1]. However, previous research has revealed biological differences depending on the age of onset of JIA, independent of the classification based on the number of joints involved [2].

Objectives: In this parent-led study, the age of onset of JIA by both disease subtype and sex of the child were explored, to identify whether there is a difference in age of onset of JIA between males and females.

Methods: An online survey was shared via social media, targeted at parents of children and young people (CYP) with JIA. Questions probed the age of symptom-onset and diagnosis (by single year of age), JIA subtype and Rheumatoid Factor (RF) status.

Results: Of the 409 CYP included, 296 had polyarticular (pol) or oligoarticular (oligo) JIA, including extended-oligo JIA (72% of all respondents).

There were no differences between onset among these subtypes; therefore, they were grouped for further analysis, given comparable disease progression and genetic markers among these subtypes. There was no significant difference regarding age of symptom onset between RF-positive and RF-negative CYP. Amongst those with poly/oligo JIA, there was a clear peak of symptom-onset in the first few years of life, with over half experiencing symptoms before their third birthday, and 73% before the age of five years. Interestingly, the distribution of symptom-onset was significantly different in the poly/oligo JIA group between males and females (P=0.0093), with the onset of poly/oligo JIA appearing to occur earlier in females (Figure 1). Given that some CYP with older-onset JIA are sometimes reclassified as having enthesitis-related arthritis (ERA) when examined in adolescent services, the Mann-Whitney U Test was repeated with only those CYP with JIA onset before the age of seven years. In this case, there remained a significant difference in age of onset of poly/oligo JIA between males and females (P=0.0061).

Conclusion: The age of symptom-onset among CYP with poly/oligo JIA differs between males and females, with females tending to exhibit symptoms earlier. This appears not to be attributable to misclassification of JIA subtype, and so this knowledge may assist future diagnoses of JIA. Further research is required to identify which temporal-associated factors may be critical in JIA onset and development.

REFERENCES

Figure 1. Grouped age of onset of polyarticular and oligoarticular JIA for females and males.

Impact of Axial Spondyloarthritis on Patients’ Professional Life: Results from the Online Survey EMAS of 638 French Patients

Laurent Grange1,2, Pascal Claudépierre3, René-Marc Filpo4,5,6,7Marco Garrido-Cumbreira8, Emile Des fleurs9, Françoise Alliot Launois10,11, Laure Gossec1,12.

1 Grenoble Alpes University Hospital, Rheumatology, Echire, France; 2 Association Française de Lutte Antirhumatismale A.F.A.R, President, Paris, France; 3 Henri Mondor University Hospital, Rheumatology, Creteil, France; 4 Lille University, Lille, France; 5 Roger Salengro University Hospital, Rheumatology, Lille, France; 6 Universidad de Sevilla, Sevilla, Spain; 7 Health and Territory Research (HTR), Sevilla, Spain; 8 Spanish Federation of Spondyloarthritis Associations (CAEDE), Madrid, Spain; 9 Novartis Pharma, Medical affairs, Rueil Malmaison, France; 10 Association Française de Lutte Antirhumatismale A.F.A.R, Vice-president, Paris, France; 11 Sorbonne University, Paris, France; 12 La Pitié-Sapétière University Hospital, Rheumatology, Paris, France

Background: Axial spondyloarthritides (axSpA) can result in functional disability due to their axSpA. Axial spondyloarthritis (axSpA) results in functional limitations and work disability. However, there are little data in the era of biologics.

Objectives: The aim of this analysis was to evaluate the impact of axSpA on professional life.

Methods: Between December 2017 and February 2018, patients followed for axSpA by their rheumatologists or affiliated to the French patients association AFLAR, and self-reporting axSpA, participated in the European Map of Axial Spondyloarthritis (EMAS) cross-sectional patient survey1. Socio-demographics (age, gender, relationship status, educational level, job status), disease activity (BASDAI) and the impact of axSpA on professional life (job choice, working hours, sick leave, unemployment and relationship with colleagues) were collected. The participants who were employed and working at the time of the survey were regrouped as “employed” and the ones employed or on temporary sick leave or students at the time of the survey as “active”. No imputation of missing data was performed and the analyses were descriptive.

Results: In France, 638 persons (mean age 41.5 ± 11.1 years, 77% females, mean disease duration 6.9±8.2 years, mean BASDAI 5.9±1.7) participated to the survey. About half of them (51%) had a university degree. At the time of the survey, 54% were employed, 26% in temporary or permanent sick leave, 7% unemployed, 6% retired, 5% homemaker and 2% students. Overall, 176 (28%) received social compensation for handicap or disability due to their axSpA. Regarding the employed ones (n=331), 50% were unskilled workers, 15% had an intermediate profession and 23% a white-collar job. The majority (73%) reported working issues related to axSpA in the last 12 months, such as sick leave (60%), reducing or difficulties to fulfill working hours (62%) or missing working hours for health appointments (33%). Among patients on temporary sick leave (n=72), 92% reported that it was the consequence of their axSpA and the mean duration of their temporary sick leave in the last 12 months was 5.4±4.0 months. Considering active people (n=418), 39% declared that their relationships with their work colleagues were worse since their axSpA. AxSpA had also influenced 55% of them in their job choice and drove 44% to adapt their workplace and 34% to move to another job. Finally, 62% expressed their fear to lose their job because of axSpA.

Conclusion: In this survey of 638 young axSpA patients, 66% of participants were active; the impact of the disease on professional life was described as important and often had consequences including permanent sick leave or unemployment. These aspects of axSpA should be better assessed.

REFERENCE
Building patient led organisations

PARE0018  ENABLING PATIENT-CENTRED CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES

Neil Betteridge1, Alejandro Balsa2, Maya Buch3, Maxime Dougdos4, Patrick Durez5, Ennio Favalli6, Guillaume Favier7, Clem Gabay8, Rinie Geenen9, Ioanna Gouni-Berthold10, Frank van den Hoogen11, Alison Kent12, Anne Grete Semb13, Magnus Skild14, Tore K. Kvien15, Betreder Associates, London, United Kingdom; Hosp Uni La Paz, Madrid, Spain; hapel Allerton Hospital, Uni of Leeds, Leeds, United Kingdom; Cochinn Hosp, Paris, France; Rheum, Clin Uni St-Luc, IREC, Brussels, Belgium; Gaetano Pini Inst, Milan, Italy; Global Strategy Group, KPMG LLP, London, United Kingdom; Geneva Uni Hosp, Geneva, Switzerland; Dept of Psychology, Utrecht Uni, Utrecht, Netherlands; Polyclinic for Endocrinology, Diabetes and Preventive Medicine, Uni Cologne, Cologne, Germany; Sint Maartenskliniek, Nijmegen, Netherlands; Salisbury NHS Foundation Trust Hosp, Salisbury, United Kingdom; Karolinska Institutet and Karolinska Uni Hosp, Stockholm, Sweden; Rigshospitalet, Copenhagen, Denmark; Inst Rheumatology, Prague, Czech Republic; Hosp Santa Maria, Lisbon, Portugal; Diakonhjemmet Hosp, Oslo, Norway

Background: Patients with rheumatoid arthritis (RA) have an increased risk of comorbidities such as diabetes (IR of 8.6 per 1000 person-years); 20% prevalence), interstitial lung disease (7.7% incidence); and cardiovascular disease (40-70%); 5-12.9% mortality) which contributes to increased long-term morbidity and mortality. However, despite advances in treatment there are few established recommendations on the management of RA-related comorbidities.

Objectives: This study aimed to identify examples of good practice in the care of RA and associated comorbidities meeting standards of patient-centred care, and consider how these could be implemented in other European centres.

Methods: Following a literature review, multidisciplinary teams including specialists in rheumatology, cardiology and internal medicine, nurses, physiotherapists, psychologists, patient liaisons and care coordinators at 12 selected specialist centres across Europe (1 centre per country) were interviewed (approx. 180 interviews). The models identified were critically reviewed by a group of experts including a patient representative, and the degree to which the interventions impacted patient care and could be implemented in other centres was evaluated.

Results: Several care model interventions were identified which may improve quality and the patient's experience of care, e.g. fully integrated screening and diagnosis of comorbidities; coordination and sharing of care across different disciplines of comorbidity management; tailored individual education of patients and family members on lifestyle; enabling virtual engagement between patients on lifestyle management; and optimised convenience for patients having to attend multiple specialty appointments.

Conclusion: This study identified and evaluated interventions that may contribute to increased long-term morbidity and mortality (9). How-